| | | Today's news release for brigatinib:
the confirmed intracranial objective response rate (ORR) was 53 percent in the Phase 1/2 trial, and the confirmed intracranial ORR was 67 percent in Arm B (brigatinib 180 mg with seven-day lead-in at 90 mg once daily) in the ALTA trial. Median intracranial progression-free survival (PFS) in ALTA Arm B was 18.4 months.
Alectinib CNS response:
www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/
Across both studies, 60% of patients had known CNS metastases at the time of enrollment, and of these patients, 51 had baseline measurable CNS lesions. The response rate among these 51 patients was 61%, and median duration of intracranial response was 9.1 months.
www.journalofclinicalpathways.com/news/alectinib-curbs-cns-metastases-some-advanced-lung-cancer
Alectinib, also an ALK inhibitor, has demonstrated activity in the CNS and the team sought to further evaluate its efficacy by studying data on 136 alectinib treated crizotinib-refractory patients with CNS metastases - 60% of the overall study population. Of this group, 50 had measurable CNS disease at baseline.
In the latter group, the objective response rate (ORR) at a median follow-up of 12.4 months was 64.0%, the CNS disease control rate was 90% and the median CNS duration of response was 10.8 months.
When all 136 patients were included, the corresponding ORR was 42.6%, the CNS disease control rate was 85.3% and the median CNS duration of response was 11.1 months. In the 95 patients with prior radiotherapy, the ORR was 35.8% and for those who had not had radiotherapy, it was 58.5%.
Ceritinib CNS response:
www.ascopost.com/News/16284
The median duration of response was 9.7 months and a median progression-free survival of 8.2 months (95% CI = 6.7–10.1) for patients with and without CNS metastases
In the 124 patients who started the study with brain metastases, ceritinib achieved an overall response rate of 54.0% (95% CI = 44.9%–63.0%) and a median progression-free survival of 6.9 months (95% CI = 5.4–8.4).
My take away:
PFS (months) for patients with CNS metastases:
brigatinib: 18 mos.
alectinib: 9-11 mos.
ceritinib: 7 mos.
GA |
|
